Ajinomoto CELLiST Korea launches CELLiST AAV Production Supplement 1
Supplement was developed through collaboration between Ajinomoto Co., Inc. (Tokyo, Japan) and its US-based consolidated subsidiary, Forge Biologics
8 Jan 2026Product news
CELLiST™ AAV Production Supplement 1
Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group specializing in the development and manufacturing of cell culture media, has launched its CELLiST™ AAV Production Supplement 1, a newly developed medium supplement designed to significantly enhance viral vector productivity in gene therapy manufacturing.
The supplement was developed through collaboration between Ajinomoto Co., Inc (Tokyo, Japan) and its US-based consolidated subsidiary, Forge Biologics, a CDMO specializing in adeno-associated virus (AAV) development and manufacturing.
The advancement addresses one of the most critical challenges in the fast-growing gene therapy field — improving productivity while reducing manufacturing costs. Demonstration studies confirmed that CELLiST™ AAV Production Supplement 1 improves the productivity of viral vector manufacturing by 1.3 to 2 times (based on Ajinomoto CELLiST Korea’s culture conditions) compared to conventional culture methods.
CELLiST™ guarantees excellence through GMP-compliant manufacturing, ensuring consistent quality and minimizing contamination risks for reliable gene therapy production. It is chemically-defined and guaranteed to be animal origin free (AOF), to ensure consistent quality.
“We are excited to introduce CELLiST™ AAV Production Supplement 1 to our customers,” said President Sugiyama of Ajinomoto CELLiST Korea. “Building on the Ajinomoto Group’s strong R&D foundation, our goal is to help gene therapy developers achieve higher productivity, better scalability, and more reliable outcomes in their manufacturing processes.”